<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39344100</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>06</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1941-5923</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><PubDate><Year>2024</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>The American journal of case reports</Title><ISOAbbreviation>Am J Case Rep</ISOAbbreviation></Journal><ArticleTitle>Otitis Media with ANCA-Associated Vasculitis Following COVID-19 mRNA Vaccination: A Case Report.</ArticleTitle><Pagination><StartPage>e945301</StartPage><MedlinePgn>e945301</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e945301</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.12659/AJCR.945301</ELocationID><Abstract><AbstractText>BACKGROUND SARS-CoV-2 caused a worldwide pandemic, and mRNA vaccines against the SARS-CoV-2 spike protein were developed to avoid SARS-CoV-2 infection. Short-term adverse events, such as fever, malaise, body aches, and headaches, develop within a few days following COVID-19 vaccination. Those adverse events are common and widely known as transient reactions. Recently, an association with COVID-19 vaccine as an inducer of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis has been noted. Furthermore, a relationship between COVID-19 vaccination and the development of autoimmune diseases has been reported and termed rheumatoid immune-mediated inflammatory disease. However, the mechanisms of the immune response following COVID-19 vaccination in relation to ANCA-associated vasculitis development remain unclear. CASE REPORT We report a case of a female patient who developed otitis media with ANCA-associated vasculitis following the third dose of COVID-19 mRNA vaccination. A 74-year-old woman presented with bilateral hearing loss and malaise for 1 month after COVID-19 vaccination. Serum myeloperoxidase-ANCA levels were confirmed to be elevated, and pure-tone audiometry revealed moderate bilateral mixed hearing loss. Treatment with steroids and rituximab led to recovery of hearing loss and a reduction in myeloperoxidase-ANCA titre. CONCLUSIONS The pathogenesis of adverse events following COVID-19 vaccination are still unclear. This report has indicated that ANCA-associated vasculitis can be related to COVID-19 mRNA vaccines. As our knowledge of autoimmune disease developing after COVID-19 vaccination is still in the accumulation phase, it is relevant to amass such case reports and use them for assistance in diagnosis in the future.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yoshino</LastName><ForeName>Yuta</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Saitama Citizens Medical Center, Saitama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamanaka</LastName><ForeName>Yurika</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Saitama Citizens Medical Center, Saitama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oda</LastName><ForeName>Aya</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Saitama Citizens Medical Center, Saitama, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Case Rep</MedlineTA><NlmUniqueID>101489566</NlmUniqueID><ISSNLinking>1941-5923</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056648" MajorTopicYN="Y">Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010033" MajorTopicYN="Y">Otitis Media</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of interest:</b> None declared</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>1</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39344100</ArticleId><ArticleId IdType="pmc">PMC11452142</ArticleId><ArticleId IdType="doi">10.12659/AJCR.945301</ArticleId><ArticleId IdType="pii">945301</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cheng H, Peng Z, Luo W, et al. Efficacy and safety of COVID-19 vaccines in phase III trials: A meta-analysis. Vaccines(Basel) 2021;9:582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8228087</ArticleId><ArticleId IdType="pubmed">34206032</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383:2603–15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403–16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Theodorou DJ, Theodorou SJ, Axiotis A, et al. COVID-19 vaccine-related myositis. QJM. 2021;114:424–25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7989152</ArticleId><ArticleId IdType="pubmed">33647971</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollard AJ, Bijker EM. A guide to vaccinology: From basic principles to new developments. Nat Rev Immunol. 2020;21:83–100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7754704</ArticleId><ArticleId IdType="pubmed">33353987</ArticleId></ArticleIdList></Reference><Reference><Citation>Molnár A, Studinger P, Ledó N. Diagnostic and therapeutic approach in ANCA-associated glomerulonephritis: A review on management strategies. Front Med. 2022;9:884188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9205443</ArticleId><ArticleId IdType="pubmed">35721093</ArticleId></ArticleIdList></Reference><Reference><Citation>Nune A, Durkowski V, Pillay SS, et al. New-onset rheumatic immune-mediated inflammatory diseases following SARS-CoV-2 vaccinations until May 2023: A systematic review. Vaccines (Basel) 2023;11:1571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10610967</ArticleId><ArticleId IdType="pubmed">37896974</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CC, Chen HY, Lu CC, Lin SH. Case Report: Anti-neutrophil cytoplasmic antibody-associated vasculitis with acute renal failure and pulmonary hemorrhage may occur after COVID-19 vaccination. Front Med. 2021;8:765447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8632021</ArticleId><ArticleId IdType="pubmed">34859017</ArticleId></ArticleIdList></Reference><Reference><Citation>Harabuchi Y, Kishibe K, Tateyama K, et al. Clinical features and treatment outcomes of otitis media with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (OMAAV): A retrospective analysis of 235 patients from a nationwide survey in Japan. Mod Rheumatol. 2017;27:87–94.</Citation><ArticleIdList><ArticleId IdType="pubmed">27166750</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh M, Merkel PA, Peh CA, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020;382:622–31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7325726</ArticleId><ArticleId IdType="pubmed">32053298</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, Kang J, Lee SG, et al. COVID-19 vaccination-related small vessel vasculitis with multiorgan involvement. Z Rheumatol. 2022;81:509–12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9118190</ArticleId><ArticleId IdType="pubmed">35587834</ArticleId></ArticleIdList></Reference><Reference><Citation>Thammathiwat T, Banjongjit A, Iampenkhae K, et al. ANCA associated glomerulonephritis following SARS-CoV-2 vaccination: A case series and systematic review. Vaccines (Basel) 2023;11:983.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10223042</ArticleId><ArticleId IdType="pubmed">37243087</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirai T, Suzuki J, Kuniyoshi S, Tanno Y, Fujii H. Granulomatosis with polyangiitis following Pfizer-BioNTech COVID-19 vaccination. Mod Rheumatol Case Rep. 2023;7:127–29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8903471</ArticleId><ArticleId IdType="pubmed">35246689</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshayes S, Dolladille C, Dumont A, et al. A worldwide pharmacoepidemiological update of drug-associated anca-associated vasculitis at the time of targeted therapies. Ann Rheum Dis. 2021;80:270.</Citation></Reference><Reference><Citation>Teijaro JR, Farber DL. COVID-19 vaccines: Modes of immune activation and future challenges. Nat Rev Immunol. 2021;21:195–97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7934118</ArticleId><ArticleId IdType="pubmed">33674759</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar N, Admane N, Kumari A, et al. Cytotoxic T-lymphocyte elicited vaccine against SARS-CoV-2 employing immunoinformatics framework. Sci Rep. 2021;11:7653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8027208</ArticleId><ArticleId IdType="pubmed">33828130</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>